Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lineage Cell Therapeutics (LCTX) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Q3 2025 value amounting to 0.44%.

  • Lineage Cell Therapeutics' Return on Capital Employed fell 1700.0% to 0.44% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.44%, marking a year-over-year decrease of 1700.0%. This contributed to the annual value of 0.23% for FY2024, which is 300.0% up from last year.
  • Lineage Cell Therapeutics' Return on Capital Employed amounted to 0.44% in Q3 2025, which was down 1700.0% from 0.39% recorded in Q2 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' Return on Capital Employed peaked at 0.21% during Q4 2022, and registered a low of 0.47% during Q4 2021.
  • Moreover, its 5-year median value for Return on Capital Employed was 0.27% (2023), whereas its average is 0.3%.
  • Its Return on Capital Employed has fluctuated over the past 5 years, first plummeted by -1900bps in 2021, then soared by 2600bps in 2022.
  • Lineage Cell Therapeutics' Return on Capital Employed (Quarter) stood at 0.47% in 2021, then surged by 55bps to 0.21% in 2022, then plummeted by -39bps to 0.29% in 2023, then increased by 18bps to 0.24% in 2024, then plummeted by -84bps to 0.44% in 2025.
  • Its last three reported values are 0.44% in Q3 2025, 0.39% for Q2 2025, and 0.21% during Q1 2025.